Literature DB >> 23147056

Correlation between resistance to pyrazinamide and resistance to other antituberculosis drugs in Mycobacterium tuberculosis strains isolated at a referral hospital.

Leila de Souza Fonseca1, Anna Grazia Marsico, Gisele Betzler de Oliveira Vieira, Rafael da Silva Duarte, Maria Helena Féres Saad, Fernanda de Carvalho Queiroz Mello.   

Abstract

The correlation between resistance to pyrazinamide (PZA) and resistance to other first-line antituberculosis drugs was investigated in 395 Mycobacterium tuberculosis strains isolated from clinical specimens, representing 14% of the overall number of M. tuberculosis isolates obtained between 2003 and 2008 at the laboratory of a referral university hospital for tuberculosis. A high correlation was found between resistance to PZA and multidrug resistance, as well as between PZA resistance and resistance to rifampin, isoniazid, and ethambutol (p < 0.01 for all). These results highlight the importance of performing PZA susceptibility testing prior to the prescription of this drug in order to treat drug-resistant and multidrug-resistant tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23147056     DOI: 10.1590/s1806-37132012000500013

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN: 1806-3713            Impact factor:   2.624


  4 in total

1.  Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT.

Authors:  Michael G Whitfield; Robin M Warren; Elizabeth M Streicher; Samantha L Sampson; Frik A Sirgel; Paul D van Helden; Alexandra Mercante; Melisa Willby; Kelsey Hughes; Kris Birkness; Glenn Morlock; Annelies van Rie; James E Posey
Journal:  J Clin Microbiol       Date:  2015-08-19       Impact factor: 5.948

2.  Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru.

Authors:  R I Calderón; G E Velásquez; M C Becerra; Z Zhang; C C Contreras; R M Yataco; J T Galea; L W Lecca; A L Kritski; M B Murray; C D Mitnick
Journal:  Int J Tuberc Lung Dis       Date:  2017-08-01       Impact factor: 2.373

3.  Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.

Authors:  Hui Xia; Susan van den Hof; Frank Cobelens; Yang Zhou; Bing Zhao; Shengfen Wang; Yanlin Zhao
Journal:  BMC Infect Dis       Date:  2020-01-07       Impact factor: 3.090

Review 4.  A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis.

Authors:  Michael G Whitfield; Heidi M Soeters; Robin M Warren; Talita York; Samantha L Sampson; Elizabeth M Streicher; Paul D van Helden; Annelies van Rie
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.